X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs LUPIN - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA LUPIN AUROBINDO PHARMA/
LUPIN
 
P/E (TTM) x 13.7 40.5 33.8% View Chart
P/BV x 2.8 2.5 112.8% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AUROBINDO PHARMA   LUPIN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
LUPIN
Mar-19
AUROBINDO PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs809986 82.0%   
Low Rs504720 70.0%   
Sales per share (Unadj.) Rs281.1369.5 76.1%  
Earnings per share (Unadj.) Rs41.413.4 308.5%  
Cash flow per share (Unadj.) Rs50.937.4 136.1%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.4303.7 65.6%  
Shares outstanding (eoy) m585.88452.49 129.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.32.3 101.2%   
Avg P/E ratio x15.963.6 24.9%  
P/CF ratio (eoy) x12.922.8 56.5%  
Price / Book Value ratio x3.32.8 117.2%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,630386,064 99.6%   
No. of employees `00017.317.7 98.0%   
Total wages/salary Rs m21,30831,513 67.6%   
Avg. sales/employee Rs Th9,500.79,453.8 100.5%   
Avg. wages/employee Rs Th1,229.41,782.0 69.0%   
Avg. net profit/employee Rs Th1,397.9343.0 407.6%   
INCOME DATA
Net Sales Rs m164,666167,182 98.5%  
Other income Rs m1,0203,640 28.0%   
Total revenues Rs m165,686170,822 97.0%   
Gross profit Rs m37,71828,822 130.9%  
Depreciation Rs m5,58010,850 51.4%   
Interest Rs m7773,078 25.2%   
Profit before tax Rs m32,38018,534 174.7%   
Minority Interest Rs m31-89 -35.2%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m8,1839,017 90.7%   
Profit after tax Rs m24,2296,066 399.5%  
Gross profit margin %22.917.2 132.9%  
Effective tax rate %25.348.7 51.9%   
Net profit margin %14.73.6 405.6%  
BALANCE SHEET DATA
Current assets Rs m121,878138,536 88.0%   
Current liabilities Rs m86,80661,299 141.6%   
Net working cap to sales %21.346.2 46.1%  
Current ratio x1.42.3 62.1%  
Inventory Days Days13084 155.0%  
Debtors Days Days68112 60.8%  
Net fixed assets Rs m81,037127,516 63.6%   
Share capital Rs m586905 64.7%   
"Free" reserves Rs m116,218136,517 85.1%   
Net worth Rs m116,804137,422 85.0%   
Long term debt Rs m4,51266,417 6.8%   
Total assets Rs m211,052279,494 75.5%  
Interest coverage x42.77.0 607.7%   
Debt to equity ratio x00.5 8.0%  
Sales to assets ratio x0.80.6 130.4%   
Return on assets %11.83.3 362.2%  
Return on equity %20.74.4 470.0%  
Return on capital %27.48.9 307.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72759,414 135.9%   
Fx outflow Rs m34,70022,282 155.7%   
Net fx Rs m46,02737,132 124.0%   
CASH FLOW
From Operations Rs m19,54816,660 117.3%  
From Investments Rs m-19,570-32,825 59.6%  
From Financial Activity Rs m8,6427,441 116.1%  
Net Cashflow Rs m8,922-8,724 -102.3%  

Share Holding

Indian Promoters % 54.1 46.6 116.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.0 11.3 70.4%  
FIIs % 27.7 31.9 86.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.1 101.0%  
Shareholders   69,601 98,259 70.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - PANACEA BIOTECH COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS